Skip to main content
Premium Trial:

Request an Annual Quote

Danaher's Acquisition of Genetix Group Nearly Complete

NEW YORK (GenomeWeb News) – Danaher said yesterday that it has acquired and received acceptances for approximately 97 percent of the currently issued shares of Genetix Group.

Danaher said that it intends to acquire any common shares of Genetix that remain untendered through the compulsory acquisition provisions for UK companies.

In December, Danaher, based in Washington, DC, offered to buy New Milton, UK-based Genetix Group for around ₤63.4 million ($102 million), or 85 pence per share.

At the time, the board of directors and shareholders of Genetix representing 77 percent of its issued share capital agreed to accept the offer. Danaher had said that the deal would become firm once holders of 90 percent of Genetix's shares agreed to accept the offer.

Genetix provides imaging technologies used to develop clinical diagnostics, biotherapeutics, pharmaceuticals, and in mainstream research applications. Danaher said that combining Genetix's technology with instrumentation from Danaher's Leica Microsystems unit creates product offerings for both the clinical and research markets.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.